Receptor-directed therapy of T-cell leukemias and lymphomas

John C. Morris, Thomas A. Waldmann, John Edward Janik

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

T-Cell leukemias and lymphomas represent a less common and heterogeneous group of lymphoid neoplasms. Overall, they respond less well to chemotherapy and have a poorer prognosis than their B-cell counterparts. T-Cell tumors express a number of potential targets for receptor-directed antibody therapy; however, there is no available therapeutic monoclonal antibody for these diseases with comparable activity to that of rituximab in B-cell disorders. Despite this, alemtuzumab, a humanized anti-CD52 monoclonal antibody has demonstrated meaningful anti-tumor activity in a variety of T-cell malignancies. A number of other antibodies, modified antibodies and immunotoxins directed against targets such as CD2, CD4, CD5, CD25, CD30 and CD122 expressed on malignant T-cells are under investigation. The current status of receptor-directed antibody therapy for T-cell leukemia and lymphoma is reviewed.

Original languageEnglish (US)
Pages (from-to)235-248
Number of pages14
JournalJournal of Immunotoxicology
Volume5
Issue number2
DOIs
StatePublished - Apr 1 2008

Fingerprint

T-Cell Leukemia
T-cells
T-Cell Lymphoma
Antibodies
T-Lymphocytes
Neoplasms
B-Lymphocytes
Monoclonal Antibodies
Tumors
Immunotoxins
Cells
Therapeutics
Chemotherapy
Drug Therapy

Keywords

  • Antibody
  • Leukemia
  • Lymphoma
  • Receptor
  • T-cell

ASJC Scopus subject areas

  • Immunology
  • Toxicology

Cite this

Receptor-directed therapy of T-cell leukemias and lymphomas. / Morris, John C.; Waldmann, Thomas A.; Janik, John Edward.

In: Journal of Immunotoxicology, Vol. 5, No. 2, 01.04.2008, p. 235-248.

Research output: Contribution to journalReview article

Morris, John C. ; Waldmann, Thomas A. ; Janik, John Edward. / Receptor-directed therapy of T-cell leukemias and lymphomas. In: Journal of Immunotoxicology. 2008 ; Vol. 5, No. 2. pp. 235-248.
@article{59d790eed5f24c2a8d4a742d3a26737c,
title = "Receptor-directed therapy of T-cell leukemias and lymphomas",
abstract = "T-Cell leukemias and lymphomas represent a less common and heterogeneous group of lymphoid neoplasms. Overall, they respond less well to chemotherapy and have a poorer prognosis than their B-cell counterparts. T-Cell tumors express a number of potential targets for receptor-directed antibody therapy; however, there is no available therapeutic monoclonal antibody for these diseases with comparable activity to that of rituximab in B-cell disorders. Despite this, alemtuzumab, a humanized anti-CD52 monoclonal antibody has demonstrated meaningful anti-tumor activity in a variety of T-cell malignancies. A number of other antibodies, modified antibodies and immunotoxins directed against targets such as CD2, CD4, CD5, CD25, CD30 and CD122 expressed on malignant T-cells are under investigation. The current status of receptor-directed antibody therapy for T-cell leukemia and lymphoma is reviewed.",
keywords = "Antibody, Leukemia, Lymphoma, Receptor, T-cell",
author = "Morris, {John C.} and Waldmann, {Thomas A.} and Janik, {John Edward}",
year = "2008",
month = "4",
day = "1",
doi = "10.1080/15476910802129661",
language = "English (US)",
volume = "5",
pages = "235--248",
journal = "Journal of Immunotoxicology",
issn = "1547-691X",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Receptor-directed therapy of T-cell leukemias and lymphomas

AU - Morris, John C.

AU - Waldmann, Thomas A.

AU - Janik, John Edward

PY - 2008/4/1

Y1 - 2008/4/1

N2 - T-Cell leukemias and lymphomas represent a less common and heterogeneous group of lymphoid neoplasms. Overall, they respond less well to chemotherapy and have a poorer prognosis than their B-cell counterparts. T-Cell tumors express a number of potential targets for receptor-directed antibody therapy; however, there is no available therapeutic monoclonal antibody for these diseases with comparable activity to that of rituximab in B-cell disorders. Despite this, alemtuzumab, a humanized anti-CD52 monoclonal antibody has demonstrated meaningful anti-tumor activity in a variety of T-cell malignancies. A number of other antibodies, modified antibodies and immunotoxins directed against targets such as CD2, CD4, CD5, CD25, CD30 and CD122 expressed on malignant T-cells are under investigation. The current status of receptor-directed antibody therapy for T-cell leukemia and lymphoma is reviewed.

AB - T-Cell leukemias and lymphomas represent a less common and heterogeneous group of lymphoid neoplasms. Overall, they respond less well to chemotherapy and have a poorer prognosis than their B-cell counterparts. T-Cell tumors express a number of potential targets for receptor-directed antibody therapy; however, there is no available therapeutic monoclonal antibody for these diseases with comparable activity to that of rituximab in B-cell disorders. Despite this, alemtuzumab, a humanized anti-CD52 monoclonal antibody has demonstrated meaningful anti-tumor activity in a variety of T-cell malignancies. A number of other antibodies, modified antibodies and immunotoxins directed against targets such as CD2, CD4, CD5, CD25, CD30 and CD122 expressed on malignant T-cells are under investigation. The current status of receptor-directed antibody therapy for T-cell leukemia and lymphoma is reviewed.

KW - Antibody

KW - Leukemia

KW - Lymphoma

KW - Receptor

KW - T-cell

UR - http://www.scopus.com/inward/record.url?scp=45849131339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849131339&partnerID=8YFLogxK

U2 - 10.1080/15476910802129661

DO - 10.1080/15476910802129661

M3 - Review article

VL - 5

SP - 235

EP - 248

JO - Journal of Immunotoxicology

JF - Journal of Immunotoxicology

SN - 1547-691X

IS - 2

ER -